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Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Effectiveness estimates were based on summary statistics from individual studies.
Number of primary studies included
At least 4 primary studies were included in the review.
Methods of combining primary studies
Primary studies were combined using narrative methods.
Investigation of differences between primary studies
Results of the review
The median number of cycles of paclitaxel was 6, generating a response rate of 21% and 4% discontinuation because of toxicity. The proportion of toxic deaths was 0.4%. The number of weeks to disease progression was 16.8. The median number of cycles of docetaxel was 6, generating a response rate of 30% and 4.4% discontinuation because of toxicity. The proportion of toxic deaths was 2%. The number of weeks to disease progression was 19. The median number of cycles of vinorelbine was 9, generating a response rate of 16% and 0% discontinuation because of toxicity. The proportion of toxic deaths was 0%. The number of weeks to disease progression was 12.
Measure of benefits used in the economic analysis
Quality-adjusted progression-free survival was used as the measure of benefits. Utilities were derived using the time trade-off technique based on the opinion of healthy volunteers and 25 breast cancer patients. Benefits were not discounted which was appropriate given the short time frame of the study.
Direct costs
Direct costs were not discounted given the short time frame of the study (from the first cycle of chemotherapy until up to 3 weeks after the last cycle). Quantities and costs were reported separately. Direct costs included costs of acquisition, preparation, and administration of chemotherapy; premedications; laboratory tests; hospitalisation; clinic visits; management of adverse effects or complications; and all related physician fees. The quantity/cost boundary adopted was that of the hospital. The estimation of quantities and costs was based on actual data. Cost of drugs and supplies were based on the 1998 pharmacy order catalogue. Costs for biochemistry and hematology tests, as well as diagnostic imaging, were obtained from the Departments of Biochemistry, Microbiology, and Diagnostic Imaging. The cost of hospitalisation was based on the cost reported by the Ontario Hospital Association for a teaching hospital. The cost of oncologists' fees was obtained from the Schedule of Benefits. The price year was 1999.
